相关临床试验
220
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1885
进行中（未招募）
5
2.3%
已完成
159
72.3%
Enrolling By Invitation
2
0.9%
尚未招募
4
1.8%
招募中
25
11.4%
终止
12
5.5%
Unknown
8
3.6%
撤回
5
2.3%
暂无批准数据
- The Syn-One Test successfully detected phosphorylated alpha-synuclein in skin biopsies of 75% of patients with idiopathic REM sleep behavior disorder, closely mirroring the 73.5% conversion rate to neurodegenerative diseases within 12 years. - The NIH-sponsored Syn-Sleep Study enrolled 80 participants across 11 U.S. sites, with P-SYN positive individuals tending to be older and having longer duration of symptoms compared to negative participants. - This minimally invasive diagnostic approach could enable early detection of synucleinopathies like Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy up to a decade before clinical symptoms emerge. - The test's ability to distinguish patients with underlying alpha-synuclein pathology from those with other causes of RBD could guide prognosis and facilitate enrollment in disease prevention trials.
• Sidney Hecht received the Arizona Bioscience Pioneer Award for Lifetime Achievement for merging biology and chemistry to improve human health. • Hecht's research at ASU's Biodesign Center focuses on mitochondrial disorders, particularly Friedreich’s ataxia, a genetic neuromuscular disease. • Hecht played a key role in developing Hycamtin, a chemotherapy drug for ovarian and lung cancer, and studied the anti-tumor agent Bleomycin. • His center has developed compounds that redirect electrons in dysfunctional respiratory chains, with one in clinical trials for Friedreich’s ataxia.
